S&P 500   4,203.77 (+0.57%)
DOW   32,984.75 (+0.23%)
QQQ   349.31 (+0.38%)
AAPL   179.02 (+1.00%)
MSFT   328.30 (-0.03%)
META   270.82 (+2.30%)
GOOGL   123.18 (+0.25%)
AMZN   121.64 (+0.88%)
TSLA   202.79 (-0.56%)
NVDA   391.30 (+3.43%)
NIO   7.44 (-1.20%)
BABA   82.99 (+4.32%)
AMD   118.09 (-0.10%)
T   15.75 (+0.13%)
F   12.03 (+0.25%)
MU   68.79 (+0.87%)
CGC   0.85 (+1.80%)
GE   103.91 (+2.34%)
DIS   88.18 (+0.25%)
AMC   4.61 (+2.44%)
PFE   38.03 (+0.03%)
PYPL   62.78 (+1.27%)
NFLX   399.74 (+1.14%)
S&P 500   4,203.77 (+0.57%)
DOW   32,984.75 (+0.23%)
QQQ   349.31 (+0.38%)
AAPL   179.02 (+1.00%)
MSFT   328.30 (-0.03%)
META   270.82 (+2.30%)
GOOGL   123.18 (+0.25%)
AMZN   121.64 (+0.88%)
TSLA   202.79 (-0.56%)
NVDA   391.30 (+3.43%)
NIO   7.44 (-1.20%)
BABA   82.99 (+4.32%)
AMD   118.09 (-0.10%)
T   15.75 (+0.13%)
F   12.03 (+0.25%)
MU   68.79 (+0.87%)
CGC   0.85 (+1.80%)
GE   103.91 (+2.34%)
DIS   88.18 (+0.25%)
AMC   4.61 (+2.44%)
PFE   38.03 (+0.03%)
PYPL   62.78 (+1.27%)
NFLX   399.74 (+1.14%)
S&P 500   4,203.77 (+0.57%)
DOW   32,984.75 (+0.23%)
QQQ   349.31 (+0.38%)
AAPL   179.02 (+1.00%)
MSFT   328.30 (-0.03%)
META   270.82 (+2.30%)
GOOGL   123.18 (+0.25%)
AMZN   121.64 (+0.88%)
TSLA   202.79 (-0.56%)
NVDA   391.30 (+3.43%)
NIO   7.44 (-1.20%)
BABA   82.99 (+4.32%)
AMD   118.09 (-0.10%)
T   15.75 (+0.13%)
F   12.03 (+0.25%)
MU   68.79 (+0.87%)
CGC   0.85 (+1.80%)
GE   103.91 (+2.34%)
DIS   88.18 (+0.25%)
AMC   4.61 (+2.44%)
PFE   38.03 (+0.03%)
PYPL   62.78 (+1.27%)
NFLX   399.74 (+1.14%)
S&P 500   4,203.77 (+0.57%)
DOW   32,984.75 (+0.23%)
QQQ   349.31 (+0.38%)
AAPL   179.02 (+1.00%)
MSFT   328.30 (-0.03%)
META   270.82 (+2.30%)
GOOGL   123.18 (+0.25%)
AMZN   121.64 (+0.88%)
TSLA   202.79 (-0.56%)
NVDA   391.30 (+3.43%)
NIO   7.44 (-1.20%)
BABA   82.99 (+4.32%)
AMD   118.09 (-0.10%)
T   15.75 (+0.13%)
F   12.03 (+0.25%)
MU   68.79 (+0.87%)
CGC   0.85 (+1.80%)
GE   103.91 (+2.34%)
DIS   88.18 (+0.25%)
AMC   4.61 (+2.44%)
PFE   38.03 (+0.03%)
PYPL   62.78 (+1.27%)
NFLX   399.74 (+1.14%)
NASDAQ:AXLA

Axcella Health (AXLA) Stock Forecast, Price & News

$0.38
-0.01 (-1.74%)
(As of 11:02 AM ET)
Compare
Today's Range
$0.35
$0.40
50-Day Range
$0.35
$0.50
52-Week Range
$0.16
$2.79
Volume
33,153 shs
Average Volume
668,094 shs
Market Capitalization
$28.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.25

Axcella Health MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
1,240.0% Upside
$5.25 Price Target
Short Interest
Bearish
5.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$394 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.49) to ($1.35) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.66 out of 5 stars

Medical Sector

884th out of 1,006 stocks

Biological Products, Except Diagnostic Industry

144th out of 167 stocks


AXLA stock logo

About Axcella Health (NASDAQ:AXLA) Stock

Axcella Health, Inc. is a biotechnology company. It engages in the research and development of treatment for diseases and improves health using endogenous metabolic modulator, or EMM, and compositions. Its product pipeline includes AXA1665, for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125, for non-alcoholic steatohepatitis. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.

Receive AXLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axcella Health and its competitors with MarketBeat's FREE daily newsletter.

AXLA Stock News Headlines

Axcella Health (AXLA) Gets a Hold from H.C. Wainwright
The $193 Billion US-China War You Don't Know About
They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.
The $193 Billion US-China War You Don't Know About
They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.
H.C. Wainwright Keeps Their Hold Rating on Axcella Health (AXLA)
Axcella Health Inc. (NASDAQ:AXLA) Short Interest Update
Noble Financial Keeps Their Buy Rating on Axcella Health (AXLA)
H.C. Wainwright Reaffirms Their Hold Rating on Axcella Health (AXLA)
Why Is Axcella Health (AXLA) Stock Up 66% Today?
SVB Securities Keeps Their Buy Rating on Axcella Health (AXLA)
See More Headlines

AXLA Price History

AXLA Company Calendar

Last Earnings
3/30/2023
Today
6/01/2023
Next Earnings (Estimated)
8/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXLA
Employees
59
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.25
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+1,240.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-81,190,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.01 per share

Miscellaneous

Free Float
68,897,000
Market Cap
$28.87 million
Optionable
Not Optionable
Beta
1.56

Key Executives

  • William R. HinshawWilliam R. Hinshaw
    President, Chief Executive Officer & Director
  • Margaret Koziel
    Chief Medical Officer & Senior Vice President
  • Paul Fehlner
    Secretary, Chief Legal Officer & Senior VP
  • Dan Kirby
    SVP-Strategic Operations













AXLA Stock - Frequently Asked Questions

Should I buy or sell Axcella Health stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axcella Health in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AXLA shares.
View AXLA analyst ratings
or view top-rated stocks.

What is Axcella Health's stock price forecast for 2023?

4 analysts have issued twelve-month target prices for Axcella Health's stock. Their AXLA share price forecasts range from $2.00 to $8.00. On average, they expect the company's share price to reach $5.25 in the next twelve months. This suggests a possible upside of 1,240.0% from the stock's current price.
View analysts price targets for AXLA
or view top-rated stocks among Wall Street analysts.

How have AXLA shares performed in 2023?

Axcella Health's stock was trading at $0.3275 at the beginning of 2023. Since then, AXLA stock has increased by 19.6% and is now trading at $0.3918.
View the best growth stocks for 2023 here
.

When is Axcella Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our AXLA earnings forecast
.

How were Axcella Health's earnings last quarter?

Axcella Health Inc. (NASDAQ:AXLA) announced its quarterly earnings results on Thursday, March, 30th. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by $0.06.

What is Bill Hinshaw's approval rating as Axcella Health's CEO?

5 employees have rated Axcella Health Chief Executive Officer Bill Hinshaw on Glassdoor.com. Bill Hinshaw has an approval rating of 100% among the company's employees. This puts Bill Hinshaw in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 77.0% of employees surveyed would recommend working at Axcella Health to a friend.

What other stocks do shareholders of Axcella Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axcella Health investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Evofem Biosciences (EVFM), ADMA Biologics (ADMA), Coty (COTY), Energy Transfer (ET), Myovant Sciences (MYOV), NVIDIA (NVDA), Pfizer (PFE) and Moderna (MRNA).

When did Axcella Health IPO?

(AXLA) raised $76 million in an initial public offering on Thursday, May 9th 2019. The company issued 3,600,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and SVB Leerink served as the underwriters for the IPO.

What is Axcella Health's stock symbol?

Axcella Health trades on the NASDAQ under the ticker symbol "AXLA."

Who are Axcella Health's major shareholders?

Axcella Health's stock is owned by a variety of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.46%), Virtu Financial LLC (0.11%) and Simplex Trading LLC (0.00%). Insiders that own company stock include David R Epstein, Des Produits Nestle S Societe, Manu Chakravarthy, Margaret Koziel, Paul Fehlner, Robert Crane and William Hinshaw.
View institutional ownership trends
.

How do I buy shares of Axcella Health?

Shares of AXLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axcella Health's stock price today?

One share of AXLA stock can currently be purchased for approximately $0.39.

How much money does Axcella Health make?

Axcella Health (NASDAQ:AXLA) has a market capitalization of $28.87 million. The company earns $-81,190,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis.

How can I contact Axcella Health?

Axcella Health's mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.axcellahealth.com. The company can be reached via phone at (857) 320-2200, via email at ir@axcellahealth.com, or via fax at 617-441-6243.

This page (NASDAQ:AXLA) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -